AiCure announced the DHA PTSD-DT Program will deploy AiCure's AI platform in its post-traumatic stress disorder (PTSD) adaptive platform trial (APT) to simultaneously evaluate the efficacy of multiple PTSD treatments in both active service members and veterans.
AiCure will work with the DHA PTSD-DT Program to deploy its medication adherence platform to guide patients in their compliance to complex treatment regimens, as well as its digital biomarker solution to unobtrusively capture the subtleties of a patient's response.
Read more about the program here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.